The effect of food on the bioavailability of dolasetron mesylate tablets

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 1, 1998, Pages 17-19

  Lippert, Christina ^a   Keung, Anther ^a   Arumugham, Thangam ^a   Eller, Mark ^a   Hahne, William ^a   Weir, Scott ^a  

^a SANOFI   (France)

Author keywords

Anzemet; Dolasetron; High fat breakfast; Pharmacokinetics

Indexed keywords

DOLASETRON MESILATE; DRUG METABOLITE; HYDRODOLASETRON; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

EID: 0031908274     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-081x(199801)19:1<17::aid-bdd71>3.0.co;2-%23     Document Type: Article

References (10)

1. R. Navari, P. Hesketh, T. Grote, M. Cramer, R. Law, J. Whitmore and W. Hahne, A double-blind, randomized, comparative IV study of single dolasetron vs ondansetron in preventing cisplatin-related emesis. Proc. ASCO, 14, 522 (1995).
2. E. Rubenstein, L. Kalman, J. Hainsworth, P. Plezia, M. Modiano, P. Eisenberg, P. Hesketh, K. Frieze, J. Whitmore, M. Cramer and W. Hahne, Dose-response trial across four oral doses of dolasetron for emesis prevention after moderately emetogenic chemotherapy. Proc. ASCO, 14, 527 (1995).
3. A. Fauser, H. Bleiberg, B. Chevallier, R. Favre, M. Fabbro, N. Claverie and W. Hahne, A double-blind randomized comparative trial of IV dolasetron vs IV metoclopramide in prevention of emesis in moderately-emetogenic chemotherapy. Proc. ASCO, 14, 530 (1995).
4. W.S. Lofters and B. Zee, Dolasetron vs ondansetron with and without dexamethasone in the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur. J. Cancer, 31A, S252 (1995).
5. B. Audhuy, P. Cappelaeare and N. Claverie, Double-blind, comparative trial of the antiemetic efficacy of two IV doses of dolasetron mesilate and granisetron after infusion of high-dose cisplatin chemotherapy. Eur. J. Cancer, 31A, 5253 (1995).
6. T. Grote, M. Modiano, D. Gandara, V. Cocquyt and W. Hahne, Four arm oral dose-response trial of dolastron mesylate for prevention of emesis induced by platinum-containing moderately emetogenic chemotherapy. Eur. J. Cancer, 31A, S255 (1995).
7. 3 antagonists to dexamethasone after 24 h has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur. J. Cancer, 31A, S255 (1995).
8. J.P. Quigley and I. Meschan, Inhibition of the pyloric sphincter region by the digestion products of fat. Am. J. Physiol., 134, 803 (1941).
9. L.A. Houghton, Y.F. Mangnall and N.W. Read, Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers. Gut, 31, 1226 (1990).
10. M.B. Sidery, I.A. Macdonald and P.E. Blackshaw, Superior mesenteric artery flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals. Gut, 35, 186 (1994).